Gene and Protein Expression of Epithelial to Mesenchymal Transition for Intestinal and Anal Fistula: A Systematic Review

Nadila Haryani Osman, Ruhi Fadzlyana Jailani, Hayati Abd Rahman, Nazefah Abdul Hamid

Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Nilai, Malaysia

Purpose: Intestinal fibrosis is a common complication of inflammatory bowel diseases. However, the possible involvement of epithelial-mesenchymal transition (EMT) has been scarcely investigated. This systematic review aims to search through research papers that are focusing on messenger RNA (mRNA) and protein expression profile in EMT in fistula or in intestinal fibrosis.

Methods: Electronic exploration was performed until April 24, 2019 through PubMed, Ovid, Science Direct, and Scopus databases with the terms of “fistula” OR “intestinal fibrosis” AND “epithelial-mesenchymal transition”. Two independent reviewers scrutinized the suitability of the title and abstract before examining the full text that met the inclusion criteria. For each study, the sample types that were used, methods for analysis, and genes expressed were identified. The list of genes was further analyzed using DAVID (Database for Annotation, Visualization, and Integrated Discovery) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway.

Results: There were 896 citations found; however, only 3 studies fulfilled the requirements. Among the EMT-related genes, 5 were upregulated genes at mRNA level while 6 were at protein level. However, only 2 downregulated genes were found at each mRNA and protein level. Of the 4 inflammation-related genes found, 3 genes were upregulated at mRNA level and 1 at protein level. These genes were confirmed to be involved in the development of inflammatory induced fibrosis and fistula through EMT. Results from quantitative real-time polymerase chain reaction analysis were consistent with the process of EMT, confirmed by the western blot protein analysis.

Conclusion: Many significant genes which are involved in the process of EMT in fistula and intestinal fibrosis have been identified. With high-end technology many more genes could be identified. These genes will be good molecular targets in the development of biomarkers for precision drug targeting in the future treatment of intestinal fibrosis and fistula.

Keywords: *Intestinal fibrosis; Fistula; Epithelial-mesenchymal transition; Gene; Proteins*

INTRODUCTION

Intestinal fibrosis is defined as disproportionate deposition of extracellular matrix (ECM) as a result of chronic inflammation and

deficient intestinal wound healing with an underlying expansion of mesenchymal cells [1, 2]. This complication is commonly found in inflammatory bowel diseases (IBDs), whereby it affects more than 30% and almost 5% of patients with Crohn disease (CD) and ulcerative colitis, respectively [3-5]. Fibrosis and stricture formation frequently proceed to fistula formation, indicating that both processes may be linked or interdependent. Although most of the IBD patients exhibit inflammatory disease phenotype, one-third of them show evidence of stricture or penetrating intestinal complication at the time of diagnosis. However, the pathogenesis of fistula formation is still unknown [6]. To date there are no anti-fibrotic drugs available that can prevent or treat intestinal fibrosis, making surgery the sole therapeutic solution. Unfortunately, once the process starts the evolution of fibrosis and stric-

Received: Jun 28, 2021 • Revised: Aug 25, 2021 • Accepted: Sep 6, 2021
Correspondence to: Ruhi Fadzlyana Jailani, MBBS, Doctor Of General Surgery
Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia,
Bandar Baru Nilai, 71800 Nilai, Negeri Sembilan, Malaysia
Tel: +60-67985002, Fax: +60-67580404
E-mail: ruhi@usim.edu.my
ORCID: <https://orcid.org/0000-0002-0340-2318>

© 2021 The Korean Society of Coloproctology

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ture formation cannot be prevented through the use of anti-inflammatory drugs, be it in IBD or other chronic inflammatory-associated fibrotic conditions of various organs (liver, kidney, and lung) [7-11].

Intestinal fibrosis is the predominant factor for luminal stricture and obstruction which leads to dysfunction of the affected digestive tracts [12]. The fibrosis phenomenon is represented by disproportionate production and deposition of ECM components through the effector cell which is the activated myofibroblasts. However, the source of the myofibroblasts was previously poorly understood until novel studies suggest that a significant fragment of synthetically active myofibroblasts arises from the conversion of epithelial cells through the process of epithelial-mesenchymal transition (EMT) [13-15]. Generally, EMT is involved in both physiological and pathological processes which include embryogenesis, organ development, wound healing, tissue remodeling, tissue fibrosis, and cancer progression [6]. During the process of EMT, the epithelial cells lose their cell-cell contacts and their distinctive protein expression patterns such as epithelial cadherin (E-cadherin), catenins, and cytokeratins, and gain phenotypic characteristics of mesenchymal cells or fibroblast markers like fibroblast-specific protein-1, alpha smooth muscle actin (α -SMA) and vimentin [2, 16, 17]. This is partially due to the coordinated regulation of a unique set of transcription factors, such as Snail1, Slug, or Twist [6,18]. In this systematic review, the literatures on gene and protein expression involved in EMT for fistula or intestinal fibrosis are reviewed in order to establish the most prevalent gene/protein expression signature. By studying the gene/protein expression, we could then possibly provide new understandings into the regulation of genes in EMT in fistula or intestinal fibrosis. This study offers new knowledge in explaining the basis of identification of the changes toward the mechanism attributed by EMT in fistula or intestinal fibrosis.

METHODS

Data sources and search strategy

The search of contemporary articles was accomplished by using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies that fulfilled the inclusion criteria for the review were searched through PubMed, Ovid, Science Direct, and Scopus starting with the first original EMT article published until April 24, 2019. The following MeSH (Medical Subject Headings) terms of “fistula” OR “intestinal fibrosis” AND “epithelial-mesenchymal transition” were used.

Inclusion and exclusion criteria

Only English-language publications were incorporated for screening, while publication types without primary data, such as the letters to editors, editorials, case reports, scientific reports, conference proceedings, chapters in a book, and narrative reviews were excluded. Studies on EMT type 1 and 3, and studies not related to

EMT, fistula, or intestinal fibrosis were also excluded.

The inclusion criteria were as follows: (1) the study on gene expression in EMT type 2 in intestinal fibrosis or fistula tissue versus normal tissue, (2) analyses on human tissue only, (3) any method of measuring and analyzing protein and/or messenger RNA (mRNA) expression, and (4) where total samples used in the study were mentioned. Articles were excluded based on the following: (1) use of anything but resected human fistula or intestinal fibrosis tissue, including primary cultures, cell lines, and transfected cells or induced EMT, (2) use of animal tissue, and (3) interventional study.

Identification of relevant studies and data extraction

All articles from searchers were downloaded into an EndNote library (EndNote Software ver. X4.0.1, Clarivate, Philadelphia, PA, USA). Manuscripts retrieved from the database searches were screened by the titles, the abstracts, and the entire articles to select the relevant studies. The screenings were conducted by 2 reviewers. The duplicated papers were discarded by EndNote Software. Full-text articles references were obtained and examined by 2 reviewers to meet the preset inclusion criteria. A third author was consulted on the eligibility where there were disagreements between the reviewers. Records on reasons for elimination were kept.

From the studies included, the data were extracted were tabulated by 1 author. Each study includes in detail the author, year of study, study design, sample size, sampling type, and method for gene analysis, and the gene identified were tabulated. Data entry was also ensured for each study after completing data extraction.

Study quality and analysis

The research quality was assessed by discussing the reported details of analysis among the authors. The authors focused on the results and the reported list of gene expressions. To verify the validity of the eligible studies, reviewers worked independently and with adequate reliability. For each study, bias was excluded by adhering to the inclusion criteria. The genes listed were further analyzed with the DAVID (Database for Annotation, Visualization, and Integrated Discovery; <https://david.ncifcrf.gov/home.jsp>) [19]. Further analysis was performed to determine the cluster of genes that displayed significant functional annotation enrichment and those enriched annotations could be related to the EMT in fistula or in intestinal fibrosis, while the contribution of genes in the pathway was based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway [20].

RESULTS

The search strategies from 4 databases yielded 896 potentially relevant titles. Of these, 786 articles were eligible and had been retrieved for abstract review after duplicates were removed. Of the 786 studies that were reviewed initially, 61 were selected for full-text analysis. After comprehensive review of 61 full reports, only 3

articles fulfilled our inclusion and exclusion criteria hence selected for this systematic review. A PRISMA diagram describing the search results is shown in Fig. 1.

In total, 8 genes and 7 proteins were identified as being overexpressed and 2 genes and 2 proteins being under-expressed in EMT in cases of intestinal fibrosis or fistula compared to normal tissue. Tables 1 and 2 summarize the features of these studies.

Two studies used IBD for the patient group whereby, mucosal tissue biopsies were taken from the colon. Zhang et al. [21] looked into the roles of interleukin (IL)-17A and EMT in the initiation and development of intestinal fibrosis while Chen et al. [22] studied the possible roles of microRNA-200b (miR-200b) in preserving intact intestinal epithelial cells (IECs) in IBDs. In another study, Ratto et al. [23] used samples from patients with cryptoglandular anal fistula to investigate the cytokine pattern that is potentially responsible for the inflammation, in assessing the evidence of EMT.

Detected genes during epithelial-mesenchymal transition process

A variety of biomarkers have been used to demonstrate the EMT process. Some are acquired and some are diminished. Gene expressions can be analyzed through many platforms such as microarray and gene sequencing as well as polymerase chain reac-

tion (PCR). Quantitative real-time PCR (qRT-PCR) was used in all studies as a platform for analysis at the mRNA level. The protein expression was identified via western blotting technique in all studies.

In this review, we found that qRT-PCR was used to demonstrate the molecular characterization of the inflammation. Gene expression of IL-1 β and IL-8 were found by Ratto et al. [23] to be higher in fistulas as compared to normal anal mucosa, with different levels of expression in the proximal and distal parts of the fistula

Table 1. Number and types of analyzed genes in the original study

Study	Year	Type of gene	
		Inflammation-related	EMT-related
Zhang et al. [21]	2018	IL-17A	Vimentin, Snail, α -SMA, E-cadherin
Chen et al. [22]	2013	NA	Vimentin, TGF- β 1, miR-200b, E-cadherin
Ratto et al. [23]	2016	IL-1 β , IL-8	TGF- β 1, Zeb 1, Snail (Snail2), Vimentin, pERK, NF- κ B, E-cadherin

EMT, epithelial-mesenchymal transition; IL, interleukin; α -SMA, smooth muscle alpha-actin; E-cadherin, epithelial cadherin; NA, not applicable; TGF- β 1, transforming growth factor beta 1; miR-200b, microRNA-200b; pERK, protein kinase RNA-like endoplasmic reticulum kinase; NF- κ B, nuclear factor kappa B.

Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of search strategy and selection process. EMT, epithelial-mesenchymal transition.

Table 2. Results of systematic literature review

Study	Year	Type and size of sample		Result
		Patient group	Control group	
Zhang et al. [21]	2018	Colonic mucosal biopsy tissue of 14 CD patients	Normal intestinal mucosal tissues adjacent to intestinal polyps of 8 patients	<ul style="list-style-type: none">• The gene and protein expression of IL-17A, vimentin, and α-SMA in colonic mucosal biopsy tissue of CD patients were significantly higher than those in control group.• mRNA level and protein expression of E-cadherin in colonic mucosal tissue from CD patients were significantly lower.• No significant differences in expression of Snail between CD and control groups in mRNA level but high protein expression at protein level.
Chen et al. [22]	2013	22 Biopsy mucosal samples of IBD patients (11 UC and 11 CD)	5 Patients with colonic polyps, which pathologically confirm benign adenoma	<ul style="list-style-type: none">• Gene and protein expression of vimentin and TGF-β1 were significantly higher in IBD group.• Gene and protein expression of miR-200b and E-cadherin were significantly lower in IBD group.
Ratto et al. [23]	2016	12 Patients with transsphincteric cryptoglandular anal fistula	3 Patients with fecal incontinence who underwent biopsy of the anal mucosa	<ul style="list-style-type: none">• Gene expression of IL-1β and IL-8 for inflammation and cytokine expression were higher than in normal anal mucosa.• Gene expression of TGF-β1, Zeb1, Snail2, and vimentin were significantly higher than in normal anal mucosa.• Protein expression of pERK and NF-κB were significantly higher than in normal anal mucosa.• Gene and protein expression of E-cadherin was significantly lower in fistula tract.

Quantitative real-time polymerase chain reaction was used to analyze gene expression and western blot for protein expression.

CD, Crohn disease; IL, interleukin; α -SMA, smooth muscle alpha-actin; mRNA, messenger RNA; E-cadherin, epithelial cadherin; TGF- β 1, transforming growth factor beta 1; IBD, inflammatory bowel disease; UC, ulcerative colitis; miR-200b, microRNA-200b; pERK, protein kinase RNA-like endoplasmic reticulum kinase; NF- κ B, nuclear factor kappa B.

tract. Meanwhile, Zhang et al. [21] found that the mRNA levels of IL-17A in colonic mucosal tissue of CD patients were significantly higher than those in the control groups.

The outcomes of the qRT-PCR analysis were consistent with a process of EMT. Among the genes analyzed, transforming growth factor beta 1 (TGF- β 1) was overexpressed in studies by Chen et al. [22] and Ratto et al. [23] while vimentin was significantly higher in all 3 studies [21-23]. Zeb-1 and Snail were found highly expressed in fistula tract [23] while α -SMA was significantly higher in colonic mucosa of CD patients [21]. A reduction of E-cadherin was found in all of these 3 studies [21-23] and miR-200b was significantly lower in IBD groups [22].

Protein expression evaluated by western blot analysis confirmed the qRT-PCR findings. E-cadherin [21-23] and miR-200b [22] were expressed only in healthy anal mucosa, protein kinase RNA-like endoplasmic reticulum kinase (pERK) and nuclear factor kappa B (NF- κ B) showed strong expression in fistula tract [23] while Snail and α -SMA were highly expressed in CD patients [21]. Vimentin [21, 22] and TGF- β 1 [22] were overexpressed in all IBD patients (Fig. 2).

Differentially expressed genes' ontology analysis

Differentially expressed genes and pathways enrichment were analyzed using DAVID [19]. From the Gene Ontology Term based on Expression Analysis Systematic Explorer (EASE) score, the positive regulation of gene expression exhibited the highest enrich term compared to the other terms which are related to this review study. A P-value of < 0.05 was used as cut-off to functionally char-

Fig. 2. Summary of 3 different studies showing the upregulated (upward arrows) and downregulated (downward arrows) genes/proteins. Different color areas represent different datasets. The overlapping areas mean the common differentially expressed genes. IL, interleukin; α -SMA, smooth muscle alpha-actin; miR-200b, microRNA-200b; E-cadherin, epithelial cadherin; TGF- β 1, transforming growth factor beta 1; pERK, protein kinase RNA-like endoplasmic reticulum kinase; NF- κ B, nuclear factor kappa B.

acterize the genes, which were found to be differentially expressed in the different types of samples. The list of the genes involved is as shown in Table 3. Based on KEGG pathway analysis, there were

Gene Ontology Term	Gene	P-value	Benjamini value
Positive regulation of gene expression	α -SMA, pERK, IL-1, TGF- β 1, vimentin	< 0.001	0.004
Inflammatory response	IL-8, IL-1, IL-17A, NF- κ B, TGF- β 1	< 0.001	0.009
Positive regulation of epithelial to mesenchymal transition	Snail, TGF- β 1	0.019	0.350
Epithelial to mesenchymal transition	Snail, TGF- β 1	0.020	0.350

The diagram illustrates the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) from simple steatosis to non-alcoholic steatohepatitis (NASH) and eventually hepatocellular carcinoma (HCC). The pathways are color-coded: green for normal/healthy pathways and red for pathways associated with disease progression.

Simple steatosis (without inflammation and fibrosis):

- Obesity:** Leads to increased IL-6, which activates IL-6R, and TNFα, which activates TNFR1. TNFα also activates the TNF signaling pathway.
- Insulin signaling pathway:** INS (Insulin) binds to INSR (Insulin Receptor), activating IRS-1/2, PI3K, Akt, and GSK-3, leading to Hepatocyte insulin resistance and Hyperinsulinemia.
- Lipogenesis:** INS binds to INSR, activating SREBP-1c, which leads to Lipogenic enzymes and De novo fatty acid synthesis, resulting in Fatty acid biosynthesis.
- Glucose:** Glucose binds to GLUT4, activating L-PK, which leads to Lipogenic enzymes and De novo fatty acid synthesis.
- Adipocyte signaling pathway:** LEP (Leptin) binds to ObR (Obese Receptor), activating AMPK, which leads to Suppression of hepatic glucose production, lipogenesis, and Fatty acid oxidation, glucose uptake.
- PPAR signaling pathway:** PPARα (Peroxisome Proliferator-Activated Receptor α) leads to Fatty acid oxidation, glucose uptake, and lipid storage, reduction of lipolysis.

Non-alcoholic steatohepatitis (NASH) (with hepatic inflammation and fibrosis):

- Adipose tissue:** LEP binds to ObR, activating AMPK, which leads to Suppression of hepatic glucose production, lipogenesis, and Fatty acid oxidation, glucose uptake.
- PPAR signaling pathway:** PPARα leads to Fatty acid oxidation, glucose uptake, and lipid storage, reduction of lipolysis.
- ER stress:** FFA (Free Fatty Acid) leads to ER stress, which activates IRE1α, JNK1/2, and PERK. IRE1α also leads to XBP1 (XBP1 mRNA Splicing) and CREB1. JNK1/2 leads to AP-1, c-Jun, and NF-κB. PERK leads to eIF2α and ATF4.
- Mitochondrial dysfunction:** FFA leads to Mitochondrial dysfunction, which leads to Lipid peroxidation and ROS (Reactive Oxygen Species).
- Inflammation:** TNFα leads to IL-1, IL-6, and TNFα, which leads to Development of steatohepatitis. TNFα also leads to FcγL, TNFα, and TNF-β, which leads to Activation of caspases and increased mitochondrial permeability, Neutrophil infiltration, and Stimulate collagen activation (collagen synthesis).
- Cell death:** FcγL, TNFα, and TNF-β lead to Cell death.
- Apoptosis:** FFA leads to FcγL, which leads to FcγL, Fas, and CASP8, leading to Apoptosis and Hepatocyte injury.
- Hepatocellular carcinoma (HCC):** FFA leads to HCC.

Other pathways:

- Cholesterol:** Cholesterol leads to Cx I, Cx II, Cx III, and Cx IV, which leads to Oxidative phosphorylation.
- Fatty acid oxidation:** FFA leads to Fatty acid oxidation, which leads to β-oxidation and H⁺.
- Cellular components:** The diagram includes various cellular components such as the Endoplasmic reticulum (ER), Mitochondria, and various signaling molecules like GSK-3, PI3K, Akt, SREBP-1c, L-PK, AMPK, PPARα, JNK1/2, IRE1α, XBP1, CREB1, AP-1, c-Jun, NF-κB, FcγL, TNFα, TNF-β, FcγL, Fas, CASP8, Bcl, Bax, Bim, and Cyt.

Fibrosis is the most typical complication in IBD, which is considered a vital factor of intestinal stricture in CD patients. However, the mechanism of intestinal fibrosis is still a moot point among surgeons, hence becomes a big issue when deciding the appropri-

Fig. 4. The KEGG pathway map of inflammatory bowel disease (map05321). The genes involved in this review study are shown in the red circles. Adapted from Kanehisa and Goto [20] (reference No. 210879), according to the Creative Commons License.

ate treatment for the patients. Therefore, a recent study suggested that there are multiple mechanisms to reverse the fibrosis by molecular technique in IBD patients [24]. Fibroblasts and the epithelial cells are the main progenitor cells of activated myofibroblasts

in intestinal fibrosis before they go through the EMT process [4, 5, 21, 25]. The complex process of EMT is characterized by losing the epithelial cell marker such as E-cadherin and gaining in the expression of mesenchymal features. The type 2 EMT processes

The EMT process is also supported by the expression of E-cadherin. A reduction of E-cadherin expression was found in all the 3 studies [21-23]. E-cadherin (a typical marker of epithelial cells) was expressed only in healthy anal mucosa but absent in the proximal part of the fistula and was slightly detectable in the distal part [23]. The expression also decreased in the inflamed mucosa of IBD in comparison with the controls at both mRNA and protein level [21, 22]. Reduction of E-cadherin with a strong expression of pERK and NF- κ B, the 2 intracellular factors which had

Snail, a typical marker (transcriptional factors) in the EMT process showed expression in patients' samples in only 2 studies which are done by Zhang et al. [21] and Ratto et al. [23]. Zhang et al. [21] found that there is no significant expression of Snail between the CD patients and control group at the mRNA level, but at the protein level, the expression shown was significantly higher than those in control groups. On the contrary, the expression of Snail was increased in patients who have fistula compared with healthy anal mucosa sample. However, there was no analysis for Snail done at the protein level [23]. Strong expression of Snail and lack in expression of E-cadherin may help to recognize the manifestation of EMT. Both of these genes contain enhancer box (E-box) sequences in their target gene promoter. However, as Snail is a specific transcriptional factor in EMT, its E-box sequence can recognize and inhibit the target gene expression which later decreases the expression of E-cadherin [29]. The discrepancy between the mRNA and protein levels in the study of Zhang et al.

[21] may be due to various factors as small sample size or sample degradation.

Zeb1, another of the master regulators of EMT transcriptional program can also bind to the E-cadherin promoter and repress its transcription, thus leads to the low expression of E-cadherin. The low expression of E-cadherin with the high expression of Zeb1 in Ratto et al. [23] may help to show the existence of EMT. They found that Zeb1 was highly expressed while E-cadherin showed low expression in the fistula tract compared with normal anal mucosa at mRNA level. Meanwhile, α -SMA that has been recognized as a vital marker for differentiation and activation of myofibroblasts has been detected as an upregulated gene in Zhang et al. [21], both at mRNA and protein level in patients' samples. The expression of α -SMA is one of the essential indicators for fibrosis. Fibrosis will develop when there is a huge number of aggregated and activated myofibroblasts which then produce and secrete a large number of ECM [4, 30].

In type 2 EMT, the process begins when inflammation occurs but will stop once the inflammation subsides, especially so during wound healing and tissue regeneration [31, 32]. However, during organ fibrosis, the EMT process will continue to respond to persistent inflammation, resulting in tissue destruction [31]. In this review, the molecular characterization of the inflammation was detected by the high expression of IL-1 β and IL-8 in fistulas samples [23] and strong expression of IL-17A in CD patients [21]. IL-17A is related to the intestinal fibrosis development [33] which was confirmed by Zhang et al. [21]. More recent studies indicated that IL-17A might induce EMT on epithelial cells to indirectly promote fibrosis in multiple organs [34-38]. The abnormality in IL-17A expression can be a diagnostic marker for precursor and development of acute and chronic diseases.

Based on the KEGG pathway analysis, IL-1, IL-17, NF- κ B, and TGF- β 1 were involved in IBD pathway. Meanwhile the NF- κ B, IL-1, IL-8, TGF- β 1, and pERK were involved in the NAFLD. The KEGG pathway of rheumatoid arthritis involved the following genes: IL-1 β , IL-8, TGF- β 1, and IL-8 [20]. These pathways involved both the EMT-related genes as well as the inflammation-related genes. The coexistence of both types of genes on these pathways demonstrated that inflammation and EMT are interrelated.

Limited numbers of studies retrieved for this review had been primarily attributed by the strict preset criteria that had to be fulfilled namely, observational study without treatment or cell or tissue induction. This is to ensure that the EMT process occurred *in vitro* without being triggered by other factors. Hence, the studies that involved the *in vivo* EMT process were excluded. Theoretically, the EMT process occurred are due to continuous response to the inflammatory process which later leads to organ fibrosis. One other limitation is the small-sized samples in all the 3 studies which showed statistically nonsignificant results. The identification of control sample was another important and challenging issue as there was no standardized normal control tissue among this

type of study, hence limiting the validity of the results. As qRT-PCR is the only method used, the list of genes is limited to the common genes involved. Microarray or next-generation sequencing analysis might be helpful in the detection of other genes that play a role in the EMT process in intestinal fibrosis.

Through this systematic review study, TGF- β 1, Zeb1, Snail, vimentin, α -SMA, IL-1, IL-8, IL-8, pERK, and NF- κ B had been identified as the genes being overexpressed genes while E-cadherin and miR-200b genes were under-expressed during the process of EMT in intestinal fibrosis. However, there is a need for a more comprehensive study on these genes and their protein expressions. These investigations will provide new insight into gene regulation and widen the basis of identification of the changes in the mechanisms of EMT in fistula or intestinal fibrosis. To date, surgery is the effective treatment for intestinal fibrosis and fistula in ano with the possibility of recurrence. The study on EMT-related genes can provide more insight into the pathophysiological course of the disease. A targeted adjunctive medical therapy can be made possible to reduce the need for surgical intervention as well as recurrence.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This research was funded by the Fundamental Research Grant Scheme awarded by the Ministry of Higher Education of Malaysia (USIM/FRGS/FPSK/055002/50317).

REFERENCES

1. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. *Sci Transl Med* 2013; 5:167sr1.
2. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: current knowledge and future perspectives. *J Crohns Colitis* 2008;2:279-90.
3. Specia S, Giusti I, Rieder F, Latella G. Cellular and molecular mechanisms of intestinal fibrosis. *World J Gastroenterol* 2012;18: 3635-61.
4. Fiocchi C, Lund PK. Themes in fibrosis and gastrointestinal inflammation. *Am J Physiol Gastrointest Liver Physiol* 2011;300: G677-83.
5. Rieder F, Fiocchi C. Mechanisms of tissue remodeling in inflammatory bowel disease. *Dig Dis* 2013;31:186-93.
6. Scharl M, Bruckner RS, Rogler G. The two sides of the coin: similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. *United European Gastroenterol J* 2016;4:506-14.

7. Hahn S, Nam MO, Noh JH, Lee DH, Han HW, Kim DH, et al. Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective. *Sci Rep* 2017;7: 2435.
8. Latella G, Sferra R, Specia S, Vetusch A, Gaudio E. Can we prevent, reduce or reverse intestinal fibrosis in IBD? *Eur Rev Med Pharmacol Sci* 2013;17:1283-304.
9. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med* 2012;18:1028-40.
10. Bettenworth D, Rieder F. Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs: a systematic review. *Fibrogenesis Tissue Repair* 2014;7:5.
11. Rockey DC, Bell PD, Hill JA. Fibrosis: a common pathway to organ injury and failure. *N Engl J Med* 2015;372:1138-49.
12. Di Gregorio J, Sferra R, Specia S, Vetusch A, Dubuquoy C, Desreumaux P, et al. Role of glycogen synthase kinase-3 β and PPAR- γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis. *PLoS One* 2017;12:e0171093.
13. Willis BC, Borok Z. TGF- β -induced EMT: mechanisms and implications for fibrotic lung disease. *Am J Physiol Lung Cell Mol Physiol* 2007;293:L525-34.
14. Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. *Proc Am Thorac Soc* 2006;3: 377-82.
15. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. *Hum Pathol* 2009;40:1365-76.
16. Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. *Hepatology* 2009;50:2007-13.
17. Sicklick JK, Choi SS, Bustamante M, McCall SJ, Pérez EH, Huang J, et al. Evidence for epithelial-mesenchymal transitions in adult liver cells. *Am J Physiol Gastrointest Liver Physiol* 2006;291: G575-83.
18. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin Invest* 2009;119:1420-8.
19. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009;4:44-57.
20. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res* 2000;28:27-30.
21. Zhang HJ, Zhang YN, Zhou H, Guan L, Li Y, Sun MJ. IL-17A promotes initiation and development of intestinal fibrosis through EMT. *Dig Dis Sci* 2018;63:2898-909.
22. Chen Y, Xiao Y, Ge W, Zhou K, Wen J, Yan W, et al. miR-200b inhibits TGF- β 1-induced epithelial-mesenchymal transition and promotes growth of intestinal epithelial cells. *Cell Death Dis* 2013;4:e541.
23. Ratto C, Litta F, Lucchetti D, Parello A, Boninsegna A, Arena V, et al. Immunopathological characterization of cryptoglandular anal fistula: a pilot study investigating its pathogenesis. *Colorectal Dis* 2016;18:O436-44.
24. Bettenworth D, Rieder F. Reversibility of stricturing Crohn's disease: fact or fiction? *Inflamm Bowel Dis* 2016;22:241-7.
25. Rieder F, Kessler SP, West GA, Bhilocha S, de la Motte C, Sadler TM, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. *Am J Pathol* 2011;179:2660-73.
26. Hay ED. An overview of epithelio-mesenchymal transformation. *Acta Anat (Basel)* 1995;154:8-20.
27. Liu CY, Lin HH, Tang MJ, Wang YK. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. *Oncotarget* 2015;6:15966-83.
28. Huber MA, Beug H, Wirth T. Epithelial-mesenchymal transition: NF- κ B takes center stage. *Cell Cycle* 2004;3:1477-80.
29. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? *Nat Rev Cancer* 2007;7:415-28.
30. Mifflin RC, Pinchuk IV, Saada JJ, Powell DW. Intestinal myofibroblasts: targets for stem cell therapy. *Am J Physiol Gastrointest Liver Physiol* 2011;300:G684-96.
31. López-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. *EMBO Mol Med* 2009;1:303-14.
32. Wynn TA. Cellular and molecular mechanisms of fibrosis. *J Pathol* 2008;214:199-210.
33. Biancheri P, Pender SL, Ammoscato F, Giuffrida P, Sampietro G, Ardizzone S, et al. The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis. *Fibrogenesis Tissue Repair* 2013;6: 13.
34. Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. *J Immunol* 2013;191:1835-44.
35. Wilson MS, Madala SK, Ramalingam TR, Gochoico BR, Rosas IO, Cheever AW, et al. Bleomycin and IL-1 β -mediated pulmonary fibrosis is IL-17A dependent. *J Exp Med* 2010;207:535-52.
36. Vittal R, Fan L, Greenspan DS, Mickler EA, Gopalakrishnan B, Gu H, et al. IL-17 induces type V collagen overexpression and EMT via TGF- β -dependent pathways in obliterative bronchiolitis. *Am J Physiol Lung Cell Mol Physiol* 2013;304:L401-14.
37. Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF- β 1-dependent and -independent mechanisms. *J Immunol* 2011;187:3003-14.
38. Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. *Arthritis Rheum* 2012;64:3726-35.